Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen announces early data on anti-angiogenesis pipeline molecules

Amgen announces early data on anti-angiogenesis pipeline molecules

14th April 2008

Amgen has published early results from studies concerning its anti-angiogenesis pipeline molecules, with the data suggesting the existence of biologic activity over a range of types of tumour.

Preclinical data announced by the company involved recombinant Fc-peptide fusion protein AMG 386 designed to inhibit Tie2 dependent stimulation of endothelial cells by by binding angiopoitins 1 and 2.

The results showed a significant reduction in tumour growth when AMG 386 was combined with either bevacizumab or motesanib, two vascular endothelial growth factor (VEGF).

Study data was presented at the 2008 annual meeting of the American Association for Cancer Research.

Roger M Perlmutter, executive vice president of research and development of Amgen, said: “Tumours depend on a reliable blood supply to grow and survive.

“By targeting angiogenesis – the process underlying the formation and growth of new blood vessels – we hope to achieve clinically meaningful control of many cancers.”

He added that these early results are encouraging as they show that blocking more than one angiogenesis pathway could offer increased potential to reduce tumour growth, which the company looks forward to investigating further.

In November 2006, Amgen announced encouraging results for its investigational VEGF inhibitor AMG 706.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.